Clinical Trials
13 trialsNCT02696993 2026-05-20
Nivolumab and Radiation Therapy With or Without Ipilimumab in Treating Patients With Brain Metastases From Non-small Cell Lung Cancer
M.D. Anderson Cancer Center
Phase 1/2 Active not recruiting
NCT02444741 2026-05-15
Pembrolizumab and Stereotactic Body Radiation Therapy or Non-Stereotactic Wide-Field Radiation Therapy in Treating Patients With Non-small Cell Lung Cancer
M.D. Anderson Cancer Center
Phase 1/2 Completed
NCT07579195 2026-05-14
Consolidative Therapy After EV + Pembrolizumab in Muscle Invasive Bladder Cancer, REINFORCE Trial
University of Washington
Phase 1/2 Not yet recruiting
NCT03604978 2026-05-13
Nivolumab and Multi-fraction Stereotactic Radiosurgery With or Without Ipilimumab in Treating Patients With Recurrent Grade II-III Meningioma
National Cancer Institute (NCI)
Phase 1/2 Active not recruiting
NCT03767582 2026-05-11
Trial of Neoadjuvant and Adjuvant Nivolumab and BMS-813160 With or Without GVAX for Locally Advanced Pancreatic Ductal Adenocarcinomas.
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 1/2 Completed
NCT07578467 2026-05-11
Combining Neo-adjuvant ATR-inhibition With Nodal SBRT for Early-stage Resectable HPV+ OPSCCs
University of Pennsylvania
Phase 1/2 Not yet recruiting
NCT01891318 2026-05-08
Neoadjuvant Radiosurgery for Resectable Brain Metastases: Phase I/II Study
Case Comprehensive Cancer Center
Phase 1/2 Recruiting
NCT04194554 2026-05-01
ASCLEPIuS
University of Michigan Rogel Cancer Center
Phase 1/2 Active not recruiting
NCT07535463 2026-04-17
A Study of Ivonescimab, Chemotherapy, and Stereotactic Radiosurgery for People With Non-Small Cell Lung Cancer
Memorial Sloan Kettering Cancer Center
Phase 1/2 Recruiting
NCT05987644 2026-04-08
DURABLE
Hoosier Cancer Research Network
Phase 1/2 Recruiting
NCT03508752 2026-03-27
Neurocognitive Decline in Patients With Brain Metastases
University of Texas Southwestern Medical Center
Phase 1/2 Active not recruiting
NCT05789589 2026-03-04
ADORATION
Baptist Health South Florida
Phase 1/2 Recruiting
NCT04785287 2026-03-03
Anti-CTLA4-NF mAb (BMS986218), Nivolumab, and Stereotactic Body Radiation Therapy for the Treatment of Metastatic Solid Malignancies
M.D. Anderson Cancer Center
Phase 1/2 Terminated